Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Dr Reddys receives EIR ...

    Dr Reddys receives EIR for Srikakulam plant, shares soar

    Written by Ruby Khatun Khatun Published On 2017-09-22T10:29:39+05:30  |  Updated On 2021-08-18T15:39:02+05:30

    New Delhi: Shares of Dr Reddy's Laboratories Ltd soared by 7.5% after the company said it has received establishment inspection report (EIR) from the US Food and Drug Administration (USFDA) for part of its Srikakulam plant in Andhra Pradesh.


    The stock surged 7.47% to settle at Rs2,486.45 on BSE. During the day, it jumped 7.9% to Rs2,496.50. On NSE, shares of the company soared 7.42% to close at Rs2,486.55. The stock was the biggest gainer among the blue chips on both the key indices.


    The company's market valuation went up by Rs2,864.35 crore to Rs 41,223.35 crore. In terms of equity volume, 3.19 lakh shares of the company were traded on BSE and over 40 lakh shares changed hands on NSE during the day.


    The company has received EIR from the USFDA for its formulations manufacturing facility at Srikakulam unit II, Dr. Reddy's said in a filing to BSE. It, however, did not state if the US health regulator had made any observation in the EIR.


    In a separate filing, Dr Reddy's Laboratories said it has received zero observations for its custom pharmaceutical services facility, technology development centre, at Miyapur in Hyderabad after the audit of the facility by the USFDA.

    2 facilities Andhra Pradesh custom pharmaceutical services facility Dr Reddy Dr Reddy's Dr Reddy's Laboratories Dr Reddy's Labs EIR Establishment Inspection Report Hyderabad Miyapur Shares Srikakulam plant technology development centre USFDA zero observations 
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      3.36% of about 82,600 drugs samples found to be substandard

      3.36% of about 82,600 drugs samples found to be substandard

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs 9700 crore

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs...

      Apollo medical centre in Oman granted hospital status

      Apollo medical centre in Oman granted hospital status

      Calcutta HC sets aside Centers decision for strategic sale of Bengal Chemicals

      Calcutta HC sets aside Center's decision for strategic sale of Bengal Chemicals

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 27 May 2022 6:45 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X